These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma. Alvarez-Fernández C; Escribà-Garcia L; Caballero AC; Escudero-López E; Ujaldón-Miró C; Montserrat-Torres R; Pujol-Fernández P; Sierra J; Briones J Clin Transl Immunology; 2021; 10(4):e1268. PubMed ID: 33968404 [TBL] [Abstract][Full Text] [Related]
8. Engineered T Cells: CAR T Cell Therapy and Beyond. Johnson PC; Abramson JS Curr Oncol Rep; 2022 Jan; 24(1):23-31. PubMed ID: 35059997 [TBL] [Abstract][Full Text] [Related]
9. Recent advances in CAR T-cell therapy for lymphoma in China. Che Y; Sun X Clin Transl Oncol; 2023 Oct; 25(10):2793-2800. PubMed ID: 37062016 [TBL] [Abstract][Full Text] [Related]
10. The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy. Castagna L; Bono R; Tringali S; Sapienza G; Santoro A; Indovina A; Tarantino V; Di Noto L; Maggio A; Patti C Front Med (Lausanne); 2022; 9():1072192. PubMed ID: 36561713 [TBL] [Abstract][Full Text] [Related]
11. Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions. Chavez JC; Yassine F; Sandoval-Sus J; Kharfan-Dabaja MA Int J Hematol Oncol; 2021 Jun; 10(2):IJH33. PubMed ID: 34540198 [TBL] [Abstract][Full Text] [Related]
12. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma. Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067 [TBL] [Abstract][Full Text] [Related]
13. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Li P; Liu Y; Liang Y; Bo J; Gao S; Hu Y; Hu Y; Huang H; Huang X; Jing H; Ke X; Li J; Li Y; Liu Q; Lu P; Mei H; Niu T; Song Y; Song Y; Su L; Tu S; Wang J; Wu D; Wang Z; Xu K; Ying Z; Yang Q; Zhang Y; Shi F; Zhang B; Zhang H; Zhang X; Zhao M; Zhao W; Zhao X; Huang L; Zhu J; Qian W; Han W; Liang A Cancer Biol Med; 2023 Mar; 20(2):129-46. PubMed ID: 36861439 [TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma. Fu S; Hu Y; Huang H Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):167-174. PubMed ID: 36161292 [TBL] [Abstract][Full Text] [Related]
15. Retraction: Mechanisms of M2 Macrophage-Derived Exosomal Long Non-coding RNA PVT1 in Regulating Th17 Cell Response in Experimental Autoimmune Encephalomyelitis. Frontiers Editorial Office Front Immunol; 2021; 12():773900. PubMed ID: 34630443 [TBL] [Abstract][Full Text] [Related]
16. Retraction: Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells. Frontiers Editorial Office Front Immunol; 2019; 10():1770. PubMed ID: 31379887 [TBL] [Abstract][Full Text] [Related]
17. Challenges of driving CD30-directed CAR-T cells to the clinic. Grover NS; Savoldo B BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880 [TBL] [Abstract][Full Text] [Related]
18. Retraction: Plumbagin Ameliorates Collagen-Induced Arthritis by Regulating Treg/Th17 Cell Imbalances and Suppressing Osteoclastogenesis. Frontiers Editorial Office Front Immunol; 2020; 11():112. PubMed ID: 32038665 [TBL] [Abstract][Full Text] [Related]
19. Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Makita S; Yoshimura K; Tobinai K Cancer Sci; 2017 Jun; 108(6):1109-1118. PubMed ID: 28301076 [TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T-cells in New Zealand: challenges and opportunities. Weinkove R; George P; Ruka M; Haira TH; Giunti G N Z Med J; 2021 Sep; 134(1542):96-108. PubMed ID: 34531588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]